Pacific Biosciences is trading 6.15% higher at $2.59 alongside a sharply higher broader market; no clear company-specific announcement explaining the move has surfaced. - Supplied market context shows major U.S. indexes up more than 0.5%. - The scheduled Q3 2026 earnings report is due after the market closes on November 4 and has not yet been reported. - The upcoming results may have investors’ attention, but do not establish the reason for the gain.